{
  "abstract": "Urachal adenocarcinoma is a rare malignancy without prospective treatment trials. Management of metastatic disease is typically extrapolated from colorectal cancer (CRC) due to histologic and molecular similarities. An 80-year-old woman with metastatic urachal adenocarcinoma received sequential CRC-based therapy including first-line CAPOX plus bevacizumab, second-line FOLFIRI plus bevacizumab, third-line trifluridine/tipiracil plus bevacizumab, in addition to brief administration of regorafenib and fruquintinib in the fourth- and fifth-line setting. Oxaliplatin was discontinued after one cycle due to worsening of vision on a background of pre-existing retinopathy. The longest disease control (time to progression ~11 months) occurred with trifluridine/tipiracil plus bevacizumab. To our knowledge, this represents the first report describing use of this combination in the third-line setting for metastatic urachal carcinoma. Overall survival was 27 months. This case is hypothesis-generating for the use of modern CRC-based therapies, including anti-VEGF–containing combinations.",
  "abstract_shown": true,
  "affiliations": [
    "Leaders in Oncology Care, HCA Healthcare UK",
    "Barts Cancer Institute, Queen Mary University of London"
  ],
  "article_type": null,
  "arxiv": null,
  "author_total": 2,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Shahla Abu Naib"
    },
    {
      "affs": [
        0,
        1
      ],
      "name": "Marco Gerlinger"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/7f7zvm49bt21s.bib",
  "cited_by": 0,
  "doi": "10.3389/fonc.2026.1933091",
  "fulltext_url": null,
  "id": "7f7zvm49bt21s",
  "issns": [
    "2234-943X"
  ],
  "landing_url": "https://www.frontiersin.org/articles/10.3389/fonc.2026.1933091/full",
  "language": null,
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [],
  "openalex": null,
  "pdf_url": null,
  "pmcid": null,
  "pmid": null,
  "published": "2026-10-29",
  "publisher": "Frontiers Media SA",
  "ris": "https://research.draconitic.com/paper/7f7zvm49bt21s.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:20:14Z",
      "native_id": "10.3389/fonc.2026.1933091",
      "source": "crossref",
      "url": "https://www.frontiersin.org/articles/10.3389/fonc.2026.1933091/full"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "issn:2234-943X",
      "subfield": "oncology"
    }
  ],
  "title": "Sequential colorectal cancer–based therapy including anti-angiogenics and 3rd-line trifluridine/tipiracil-bevacizumab for metastatic urachal adenocarcinoma: a case report",
  "title_text": "Sequential colorectal cancer–based therapy including anti-angiogenics and 3rd-line trifluridine/tipiracil-bevacizumab for metastatic urachal adenocarcinoma: a case report",
  "type": "peer-reviewed",
  "updated_at": "2026-10-31T00:21:08Z",
  "url": "https://research.draconitic.com/paper/7f7zvm49bt21s",
  "venue": "Frontiers in Oncology",
  "versions": []
}